Company intelligence / Profile preview

Theraplix

Ownership: Private
Development stage: Other

Overview

Theraplix was a European pharmaceutical company founded in 1931. It developed and marketed several drugs including the antipsychotic cyamemazine. The company was acquired by Rhône Poulenc in 1956, which eventually became part of Sanofi. Its products are legacy brands within the larger Sanofi portfolio today

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

cyamemazine

Unknown

Beyond the preview

Go deeper on Theraplix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theraplix.